Company: MDCXW
Filing Date: 2025-04-25
Form Type: DRS
Source: 0001062993-25-007956
Chunk: 242

Company: Medicus Pharma Ltd.
Filing Date: 2025-04-25
Form: DRS
Chunk 242
---
 been informed that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act, and is therefore unenforceable.

<div align='center'>II-1</div>

| CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD. 
 PURSUANT TO 17 C.F.R. SECTION 200.83                    |

Item 15. Recent Sales of Unregistered Securities

In the prior three years, we have issued and sold the securities described below (giving effect to the Share Consolidation) without registering the securities under the Securities Act. None of these transactions involved any underwriter's underwriting discounts or commissions, or any public offering. We believe that each of the following issuances was exempt from registration under the Securities Act in reliance on Regulation S promulgated under the Securities Act regarding sales by an issuer in offshore transactions, Regulation D under the Securities Act, Rule 701 under the Securities Act or pursuant to Section 4(a)(2) of the Securities Act regarding transactions not involving a public offering.

The Registrant granted 812,500 stock options on October 24, 2023, each having an exercise price of C$1.16 and an expiry date of October 24, 2028, of which 50,000 were forfeited on March 15, 2024.

The Registrant granted 62,500 stock options on April 1, 2024, each having an exercise price of C$4.84 and an expiry date of April 1, 2029.

The Registrant granted 37,500 stock options on April 1, 2024, each having an exercise price of C$4.80 and an expiry date of April 1, 2029.

The Registrant issued $5,172,500 aggregate principal amount of 2025 Convertible Notes on May 3, 2024.

The Registrant granted 25,000 stock options on June 25, 2024, each having an exercise price of C$3.34 and an expiry date of June 25, 2029.

The Registrant issued approximately 2,770,047 common shares on June 28, 2024, including 1,461,250 common shares issued at $4.00 per share in the 2024 Equity Offering, 1,293,125 common shares issued upon conversion of the 2025 Convertible Notes at a conversion price